Abstract
The cut-off value of serum prostate-specific antigen (PSA) level in prediction of bone metastases and the correlation of serum PSA with the clinical stage, grade, score and the rate of bone metastases have been investigated in cases of prostate cancer (PCa).
The study population consisted of 160 patients with histologically proven PCa between April, 1993 and August, 1996. The negative predictive value and the sensitivity were the highest (94%) in patients with a serum PSA value less than 10 ng/ml.
We claim that in patients with PSA values less than 10 ng/ml whole body bone scan is not necessary.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Parker, S. L., Tong, T., Bolden, S., Wingo, P. A.: Cancer statistics, 1996. CA, 46, 5 (1996).
Oesterling, J. E.: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145, 907 (1991).
Benson, C. M., Olsson, C. A.: Prostate specific antigen and prostate specific antigen density. Cancer, 74,6, 1667 (1994).
Ernst, D. S., Hanson, J., Venner, P. M., Uro-Oncology group of Northern Alberta: Analysis of prognostic factors in men with metastatic prostate cancer. J. Urol., 146, 372 (1991).
Cheryl, T. L., Oesterling, J. E.: Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol. Clin. North Amer., 24(2), 389 (1997).
Jacobs, S. C.: Spread of prostatic cancer to bone. Urology, 21, 337 (1983).
Paulson, D. F.: The impact of current staging procedures in assessing the disease extent of prostatic adenocarcinoma. J. Urol., 121, 300 (1979).
McGregor, B., Tulloch, A. G. S., Quinlan, M. F., Lovegrove, F.: The role of bone scanning in the assessment of prostatic carcinoma. Br. J. Urol., 50, 178 (1978).
Lentle, B. C., McGowan, D. G., Dierich, H.: Technetium 99M polyphosphate bone scanning in carcinoma of the prostate. Br. J. Urol., 46, 543 (1974).
Pollen, J. J.: Bone scanning in prostatic cancer. Urology, 17, 31 (1981).
Parbhoo, S.: Serial scintiscans in monitoring patients with bone metastases. In: Stoll, B. A., Parbhoo, S. (eds): Bone Metastasis: Monitoring and Treatment. New York: Raven Press, 1983, p. 201.
Soloway, M. S., Hardeman, S. W., Hickey, D.: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61, 195 (1988).
Ohori, M., Wheeler, T. M., Scardino, P. T.: The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostatic cancer. Cancer, 74, 1 (1994).
Mellinger, G. T., Gleason, D., Bailar, J.: The histology and prognosis of prostatic cancer. J. Urol., 97, 331 (1967).
Stamey, T. A., McNeal, J. E.: Adenocarcinoma of the prostate. In: Walsh, P. C., Retik, A. B., Stamey, T. A., Vaughan, E. D. (eds): Campbell's Urology. Vol. 2, 6th Edit., W. B. Saunders Company, Philadelphia, 1992.
Merrick, M. V.: Bone scanning. Review article. Br. J. Radiol., 48, 327 (1975).
Schaffer, D. L., Pendergrass, H. P.: Comparison of enzyme, clinical radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology, 121, 431 (1976).
Maeda, H., Koizumi, M., Yoshimura, K., Yamauchi, T., Kawai, T., Ogata, E.: Correlation between bone metabolic markers and bone scan in prostatic cancer. J. Urol., 157, 539 (1997).
McCarthy, P., Pollack, H. M.: Imaging of patients with stage D prostatic carcinoma. Urol. Clin. North Am., 18, 35 (1991).
Andriole, G. L., Catalona, W. J.: Using PSA to screen for prostate cancer. The Washington University experience. Urol. Clin. North Am., 20, 647 (1993).
Haukaas, S., Roervik, J., Halvorsen, O. J., Foelling, M.: When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br. J. Urol., 79, 770 (1997).
Gleave, M. E., Coupland, D., Drachenberg, D., Cohen, L., Kwong, S., Goldenberg, S. L., Sullivan, L. D.: Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology, 47, 708 (1996).
Chybowski, F. M., Keller, J. J. L., Bergstrahl, E. J., Oesterling, J. E.: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J. Urol., 145, 313 (1991).
Oesterling, J. E., Martin, S. K., Bergstrahl, E. J., Lowe, F. C.: The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. J.A.M.A., 269, 57 (1993).
Levran, Z., Gonzalez, J. A., Diokno, A. C., Jafri, S. Z. H., Steinert, B. W.: Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br. J. Urol., 75, 778 (1995).
Rees, M. A., McHugh, T. A., Dorr, R. P., Solomon, M. H., Lee, F., Littrup, P., Ann Arbor, M. I., Gonzalez, J. A., Levran, Z., Oak, R. M. I.: Assessment of the utility of bone scan, CT scan, and lymph node dissection in staging of patients with newly diagnosed prostate cancer. Proceedings of the American Urological Association. 153, 495, 1995S, 352A.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ataus, S., Çitçi, A., Alici, B. et al. The Value of Serum Prostate Specific Antigen and other Parameters in Detecting Bone Metastases in Prostate Cancer. Int Urol Nephrol 31, 481–489 (1999). https://doi.org/10.1023/A:1007163227968
Issue Date:
DOI: https://doi.org/10.1023/A:1007163227968